CAROTID ANGIOPLASTY WITH CEREBRAL PROTECTION

Zoran Milošević¹, Bojana Žvan², Marjan Zaletel² and Miloš Šurlan¹

¹Clinical Radiology Institute and ²Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia

SUMMARY – Carotid endarterectomy (CEA) is widely used in the management of high grade carotid stenosis. It is a surgical procedure requiring general anesthesia and is suitable only for lesions located at or close to the carotid bifurcation. It has complications, including stroke, death, cranial nerve palsies, wound hematoma and cardiac complications. The risk of complications is increased in patients with recurrent carotid artery stenosis following CEA, in subjects undergoing radiotherapy to the neck, and in the presence of cardiopulmonary disease. The drawbacks of CEA have led physicians to search for alternative treatment options. Carotid angioplasty and stenting (CAS) is less invasive than CEA. The method is particularly suitable for the treatment of recurrent stenosis after previous CEA and distal internal artery stenosis, which is inaccessible for CEA. CAS does not cause cranial nerve palsies. Moreover, it does not require general anesthesia and carries a lower morbidity and mortality in patients with severe cardiopulmonary disease. The complications of CAS include stroke due to distal embolization of a plaque or thrombus dislodged during the procedure, abrupt vessel occlusion due to thrombosis, dissection or vasospasm, and restenosis due to intimal hyperplasia. CAS is a relatively new procedure and it is essential to establish its efficacy and safety before it is introduced widely into clinical practice. In Slovenia, we have also started with carotid angioplasty by the study Slovenian Carotid Angioplasty Study (SCAS). According to our initial experience in 17 patients, CAS could gain more importance in stroke prevention with proper selection of patients with brain ischemia and improved cerebral protection during the procedure.

Introduction

Stroke is an important public health problem and the third most common cause of death, after heart diseases and cancer¹. In Slovenia, stroke incidence, measured as a first ever stroke per 100 000 population, is 190.5 and mortality rate is 19.3%². The proportion of ischemic stroke increases with age (33% before 45 and 80% after 50). Some 20% to 30% of all cases are supposed to be due to carotid stenosis³. The most common cause of carotid stenosis is atherosclerosis. The mechanism of brain ischemia has been thought to imply either a direct hemodynamic impact on the cerebral blood circulation or indirect as a source of thromboembolic material⁴. Three possible treatment modalities are available to prevent stroke caused by carotid stenosis. First is medical treatment, second surgical treatment, and third the newest approach, endovascular treatment by carotid angioplasty and stenting (CAS).

Platelet antiaggregants such as acetylsalicylic acid or ticlopidine reduce the risk of stroke⁵,⁶. Recently, preventive treatment with clopidogrel in combination with acetylsalicylic acid has been recommended⁷. Correcting the risk factors such as smoking, obesity, dyslipidemia, hypertension, and diabetes is necessary.

In surgical approach, the atheromatous plaque is excirpated, removed, and the artery is sutured. The first operation on carotid artery, carotid endarterectomy (CEA),
The number of the procedures increased in the following years. In 1984, 120,000 CEA operations were performed, whereafter the number of CEA began to decrease because of uncertain effectiveness. In 1991, randomized prospective surgical trials, North American Symptomatic Carotid Endarterectomy Trial (NASCET) and European Carotid Surgery Trial (ECST) demonstrated a significant stroke risk reduction by CEA compared with medical treatment in symptomatic patients with carotid stenosis greater than 70%. Reassessment of results by the American Heart Association (AHA) Stroke Council indicates that CEA was three times as effective as medical treatment in reducing the frequency of stroke. However, CEA carries a risk of complications. The benefit of CEA depends on maintaining a low complication rate. Most important complications during the procedure are perioperative stroke and death. Combined stroke and death rates exceeding 3% for patients with asymptomatic stenosis and 6% for patients with symptomatic stenosis would eliminate the benefit in stroke reduction. Postendarterectomy restenosis should also be mentioned, since it is not rare. The rate of complications associated with reoperation is high. The rate of cranial nerve injuries due to neck incision is 7.6% to 27%. CEA is the ‘gold standard’ so far, but it is not without risks and limits as regards high risk patients (elderly patients, patients suffering from coronary diseases, respiratory insufficiency...), supra-aortic lesions located in the upper section, and carotid lesions associated with severe intracranial lesions. Therefore, less invasive CAS seems to have its place in the treatment of carotid stenoses.

CAS has a history of more than 20 years. After experiments on an animal model, in 1977 Mathias proposed the treatment of carotid stenosis using angioplasty for the first time. The first carotid angioplasty was performed in 1980 by Kerber. Carotid angioplasty with or without stenting has been investigated during the last two decades. This procedure has not received wide acceptance because of the risk of embolic stroke during the procedure. Till 1997, the rate of perioperative stroke following CAS without cerebral protection ranged from 5.3% to 8.2%. Initial results were criticized for the high rate of neurologic complications. The main cause of perioperative complications are thought to be embolic particles released from the carotid plaque during angioplasty. In 1990, Theron, the ‘father’ of a cerebral protection, developed and advocated the use of a cerebral protection device during CAS. The risk of embolization and the need for cerebral protection during CAS was confirmed later.

The safety and efficacy of CAS with cerebral protection versus CEA were compared in a prospective randomized trial Carotid Revascularization Endarterectomy versus Stent Trial (CREST), launched at the beginning of 2001.

In Slovenia, we have also started with CAS by setting up the study Slovenian Carotid Angioplasty Study (SCAS), in order to evaluate the safety and efficacy of the method.

Patients and Methods

Study protocol

The study was designed as a prospective clinical trial conducted over a period of 2 years in 60 patients enrolled according to well-defined inclusion and exclusion criteria. The patients were evaluated independently by a neurologist prior to and during the procedure and follow-up examinations performed at 1, 6, 12 and 24 months. Evaluation of cerebral protection devices was incorporated in the study.

The safety of CAS was assessed on the basis of acute procedural success and occurrence of major clinical events during or within 30 days of the procedure. The efficacy of CAS was determined with respect to minor ipsilateral neurologic events, major stroke and death occurring during or within 30 days of the procedure, and recurrent stenosis established within 24 months of CAS.

Oral and written information on the study was provided to all patients, and a written, witnessed informed consent was obtained from each of them. The study was approved by the National Medical Ethics Committee.

Patients

We performed CAS in 17 patients aged 69 to 82 years, 12 male and five female. All patients were symptomatic with stenosis greater than 70%. Ten patients had suffered transient ischemic attacks, four patients minor stroke and three patients amaurosis fugax. Seven patients had stenosis of the right internal carotid artery, eight of the left internal carotid artery, and two of the right common carotid artery. Two patients had occlusion of the contralateral carotid artery. In the first six patients we did not use cerebral protection devices. In the other 11 patients cerebral protection filter devices were used.
Procedure

All patients were taking aspirin, 325 mg/d, and clopidogrel (75 mg/d) starting 7 days before the procedure. Heparin, given as an intra-arterial bolus, was titrated to maintain the activated clotting time between 200 and 250 seconds. The procedures were performed in local anesthesia. Neurologic status was monitored. Atropine (0.5-1 mg) was given as required during balloon inflation. Heart rate and blood pressure were monitored throughout the intervention.

Percutaneous access was gained through the femoral artery. Selective catheterization of carotid arteries was performed with standard techniques. Diagnostic angiography visualized the origins of the brachiocephalic arteries from the aortic arch, both carotid bifurcations, both vertebral arteries, intracranial parts of both carotid arteries and the dominant vertebral artery. Once diagnostic angiography was completed and the stenotic internal carotid artery was identified, a 5F catheter was advanced using a 0.035-inch glide wire (Terumo Radiofocus Guide Wire, Terumo, Inc.) into the ipsilateral external carotid artery. The glide wire was withdrawn and replaced with an extra stiff 0.035-inch exchange wire (Extra Stiff Amplatz Wire, 260 cm; Cook, Inc.). The 5F catheter was withdrawn, and an 8F 90-cm guiding sheath (Carotid Vista Brite Tip; Cordis, Inc.) was advanced into the common carotid artery over the exchange Amplatz wire, which was anchored in the external carotid artery. Carotid angiography was performed again to measure the vessel diameter to facilitate the sizing of balloons, stents and cerebral protection filter devices. In patients without cerebral protection, stenoses were then crossed with flexible coronary guidewires (V-18 Control Wire; Boston Scientific Corp, Watertown, Mass). Eleven patients underwent CAS with a cerebral protection filter device Angioguard (Cordis, Inc): a low-profile guidewire-based, filter-type device (4F) that was placed in the distal ICA after crossing the stenotic lesion. It captured embolic debris while maintaining distal perfusion. After that we started with the intervention on stenosis. The size of the initial angioplasty balloon was dictated by the severity of stenosis. Very severe lesions were predilated with low-profile coronary balloons ( Bypass Speedy Monorail Catheter, Boston Scientific Corp ); in case of less severe lesions, the initial dilatation might be performed with a definitive balloon sized to the distal normal artery. A Carotid Wallstent Monorail (Boston Scientific Corp) was deployed across the lesion. The stent was dilated at high pressure (14 to 16 atm) to firmly embed it into the vessel wall. After that, the filter with trapped emboli was removed and the procedure was finished. Completion angiography was performed on the ipsilateral intracranial vessels. Patients were transferred to the intensive care unit, after which the sheaths were removed. Patients were discharged on either the first or second day after the procedure. Clopidogrel was continued for 3 weeks, and aspirin was continued permanently.

Results

Procedural results are summarized in Table 1. Technical success (<30% residual stenosis) was achieved in all cases. In 14 patients, no residual stenosis was found, whereas 15% residual stenosis persisted in two, and 30% residual stenosis in one patient.

In one patient (Patient 5, Table 1), hyperperfusion syndrome occurred. It occurred in a 72-year-old female with carotid stenosis of more than 90%, who had suffered amaurosis fugax in the past. Stenting was performed successfully without residual stenosis and immediate complications (Fig. 1). On day 5 after CAS, generalized seizure with Tod’s hemiparesis on the right side occurred. Upon admission, we performed brain CT, which showed a small subarachnoid hemorrhage frontally on the left side (Fig. 2). She recovered completely after a week.

Periprocedural stroke occurred in one patient (Patient 6, Table 1). It was a 67-year-old male with a previous minor stroke and 90% stenosis of the left internal carotid artery due to a lipid-laden plaque and occluded right carotid artery. In this case, we used a cerebral protective filter. CAS was successfully performed (Fig. 3). Cerebral embolism occurred during filter removal. He developed aphasia and hemiplegia. The embolus at the middle cerebral artery bifurcation was dissolved by intra-arterial thrombolysis using rTPA (Fig. 4).

In 15 patients, CAS was performed without complications. In all patients, follow-up (average follow-up period of 3 months) revealed no transient ischemic attacks or new strokes. All patients remained at their neurologic baseline. Long-term clinical or imaging follow-up data are not yet available.

Discussion

Over the last years angioplasty has been successfully used in coronary and peripheral disorders and has also
Table 1. Procedure results in 17 patients

<table>
<thead>
<tr>
<th>Pt</th>
<th>Vessel</th>
<th>Symptoms</th>
<th>Age, y</th>
<th>CLO</th>
<th>Pre</th>
<th>Post</th>
<th>Procedure</th>
<th>Stenosis</th>
<th>Severe CAD</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>R ICA</td>
<td>TIA</td>
<td>74</td>
<td>90</td>
<td>0</td>
<td>No</td>
<td>Yes</td>
<td>99</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>L ICA</td>
<td>Stroke</td>
<td>72</td>
<td>Yes</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>70</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>R ICA</td>
<td>TIA</td>
<td>63</td>
<td>70</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>68</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>R CCA</td>
<td>TIA</td>
<td>68</td>
<td>80</td>
<td>0</td>
<td>No</td>
<td>Yes</td>
<td>56</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>L ICA</td>
<td>Amaurosis fugax</td>
<td>72</td>
<td>95</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>0.5</td>
<td>No</td>
<td>After five days, an episode of seizure and transient Tod’s hemiparesis occurred. CT of the brain showed small subarachnoid hemorrhage on the left frontal side. After a week, she recovered completely.</td>
</tr>
<tr>
<td>6</td>
<td>L ICA</td>
<td>Stroke</td>
<td>67</td>
<td>Yes</td>
<td>0</td>
<td>Yes</td>
<td>Yes</td>
<td>87</td>
<td>Yes</td>
<td>Occlusion of right ICA. Cerebral embolism occurred during filter removal. He became aphasic and had right hemiplegia. We dissolved embolus at MCA bifurcation with intra-arterial thrombolysis using rTPA, but some hemiparesis persisted.</td>
</tr>
<tr>
<td>7</td>
<td>R CCA</td>
<td>TIA</td>
<td>66</td>
<td>80</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>80</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>L ICA</td>
<td>Amaurosis fugax</td>
<td>70</td>
<td>75</td>
<td>0</td>
<td>No</td>
<td>Yes</td>
<td>75</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>R ICA</td>
<td>Stroke</td>
<td>64</td>
<td>90</td>
<td>15</td>
<td>No</td>
<td>No</td>
<td>76</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>L ICA</td>
<td>TIA</td>
<td>68</td>
<td>76</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>71</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>RICA</td>
<td>TIA</td>
<td>82</td>
<td>80</td>
<td>0</td>
<td>No</td>
<td>Yes</td>
<td>82</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>R ICA</td>
<td>TIA</td>
<td>68</td>
<td>71</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>73</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>L ICA</td>
<td>TIA</td>
<td>82</td>
<td>75</td>
<td>0</td>
<td>No</td>
<td>Yes</td>
<td>82</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>R ICA</td>
<td>TIA</td>
<td>61</td>
<td>73</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>73</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>L ICA</td>
<td>Stroke</td>
<td>76</td>
<td>93</td>
<td>30</td>
<td>No</td>
<td>Yes</td>
<td>76</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>R ICA</td>
<td>Amaurosis fugax</td>
<td>57</td>
<td>85</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>85</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>L ICA</td>
<td>TIA</td>
<td>53</td>
<td>75</td>
<td>15</td>
<td>No</td>
<td>No</td>
<td>75</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Pt, patient; CLO, contralateral carotid occlusion; CAD, coronary artery disease; R, right; ICA, internal carotid artery; L, left; CCA, common carotid artery; MCA, middle cerebral artery;

*From patient 6 on, cerebral protection filter device used.

carotid angioplasty is to prevent cerebrovascular neurologic events and not to overshadow surgery. It could be an alternative or a complement to surgery if results are comparable or better. Indications must be defined through been applied at the carotid level. Throughout the world, several teams are actively engaged in research in order to determine the indications, suitable techniques, adjunct treatments, and follow-up conditions. The final aim of
randomized multi-center studies and are currently much debated. Some would like them to be limited to high risk patients, restenosis, radiation-induced lesions, or lesions located in the upper internal carotid artery near the skull, while others would like them to be much larger, including lesions of the carotid bifurcation. Lately cerebral protection devices have the potential to enhance the safety of CAS. First report of a larger series by Wholey shows the rate of perioperative complications after CAS with cerebral protection to be 1.6%, which is significantly lower than with CEA and CAS without cerebral protection.

Now we treat all patients using a cerebral protection filter device. In all filters, we found embolic material. In two cases, filters were occluded due to a massive amount of embolic material. We suppose that in such cases a high risk of complications exists, and it is very important to know the type of plaque that can dislodge a large amount of embolic material. For the evaluation of plaque compo-
sition we performed ultrasound. We did not perform CAS in patients with echolucent plaques (type 1) due to high embolic risk. Fibrous plaques seem to carry a very low risk of rupture and embolization. We expect to learn more about plaque composition using MRI. MR additionally shows the thickness of fibrous cap and pre-existent ruptures of the plaque. By demonstrating thick or thin fibrous cap of the plaque and correlating data with the amount of emboli trapped in the filter, we could be able to analyze the risk of periprocedural complications. This information would enable better selection of patients for CAS. According to our initial experience in 17 patients, CAS could gain more importance in stroke prevention with proper selection of patients and improved cerebral protection during the procedure.

References
KAROTIDNA ANGIOPLASTIKA S CEREBRALNOM ZAŠTITOM

Z. Milošević, B. Žvan, M. Zaletel i M. Šurlan

Karotidna endarterektomija (CEA) u širokoj je uporabi pri liječenju karotidne stenoze visokog stupnja. Kirurški zahvat obavlja se u općoj anesteziji, a primjenjuje se samo pri oštećenjima na račvištu karotide ili u njegovoj neposrednoj blizini. Komplikacije koje se mogu pojaviti obuhvaćaju moždani udar, smrt, paralizu kranijskih živaca, hematom na mjestu rane i srčane komplikacije. Rizik komplikacija povećan je u bolesnika s recidivirajućom stenozom karotidne arterije nakon CEA, u bolesnika u kojih je primijenjena radioterapija u području vrata te u bolesnika s kardiopulmonalnom bolesti. Nedostatci CEA potaknuli su liječnike da potraži alternativne načine liječenja. Karotidna angioplastika uz postavljanje stenta (CAS) manje je invazivna metoda od CEA. Ona je poglavito prikladna za liječenje recidivirajućih stenoza nakon prethodne CEA te za liječenje stenoze distalnog dijela unutarnje karotidne arterije koja je nedostupna za CEA. CAS ne uzrokuje paralizu kranijskih živaca. Usto, nije nužna opća anestezija, a u bolesnika s težkom kardiopulmonalnom bolesti poboljša i smrtnost su manji. U komplikacije CAS pripada moždani udar zbog distalne embolizacije plaka ili odvajanja tromba tijekom postupka, negla okluzija krvne žile zbog tromboze, disekcija ili vezovazam te ponovna stenoza zbog hiperplazije intime. CAS je razmjerno nov postupak, pa je nužno utvrditi njegovu djelotvornost i sigurnost prije nego što se uvede u široku kliničku uporabu. U Sloveniji smo započeli s istraživanjem karotidne angioplastike u okviru projekta “Slovenian Carotid Angioplasty Study (SCAS)”. Prema našim prvim iskustvima u 17 bolesnika, CAS bi se mogao pokazati važnim u prevenciji moždanog udara, uz dobar odabir bolesnika s moždanom ishemijom i uz bolju cerebralnu zaštitu tijekom postupka.